TW202019471A - 阿茲海默症之治療及預防方法 - Google Patents
阿茲海默症之治療及預防方法 Download PDFInfo
- Publication number
- TW202019471A TW202019471A TW108126224A TW108126224A TW202019471A TW 202019471 A TW202019471 A TW 202019471A TW 108126224 A TW108126224 A TW 108126224A TW 108126224 A TW108126224 A TW 108126224A TW 202019471 A TW202019471 A TW 202019471A
- Authority
- TW
- Taiwan
- Prior art keywords
- months
- individual
- composition
- administration
- relative
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US62/702,659 | 2018-07-24 | ||
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US62/749,614 | 2018-10-23 | ||
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US62/824,162 | 2019-03-26 | ||
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US62/846,902 | 2019-05-13 | ||
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| US62/874,684 | 2019-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202019471A true TW202019471A (zh) | 2020-06-01 |
Family
ID=67551415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108126224A TW202019471A (zh) | 2018-07-24 | 2019-07-24 | 阿茲海默症之治療及預防方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (enExample) |
| EP (1) | EP3826674A2 (enExample) |
| JP (2) | JP7541505B2 (enExample) |
| KR (1) | KR20210039402A (enExample) |
| CN (2) | CN112805031A (enExample) |
| AU (1) | AU2019309938A1 (enExample) |
| BR (1) | BR112021001272A2 (enExample) |
| CA (1) | CA3107370A1 (enExample) |
| IL (3) | IL280315B2 (enExample) |
| MX (1) | MX2021000778A (enExample) |
| PH (1) | PH12021500006A1 (enExample) |
| TW (1) | TW202019471A (enExample) |
| WO (1) | WO2020023530A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| PH12022552172A1 (en) * | 2020-03-20 | 2023-12-11 | Eisai R&D Man Co Ltd | High concentration anti-aã protofibril antibody formulations and methods of use thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| US20250051427A1 (en) * | 2021-12-17 | 2025-02-13 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| KR20240142535A (ko) * | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| EP2538982A4 (en) * | 2010-02-25 | 2016-02-17 | Janssen Alzheimer Immunotherap | PET MONITORING OF IMMUNOTHERAPY TARGETED ON A-BETA |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| SG191710A1 (en) | 2011-01-21 | 2013-08-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| SI3166970T1 (sl) | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN114019170A (zh) * | 2016-01-20 | 2022-02-08 | 基因泰克公司 | 用于阿尔茨海默氏病的高剂量治疗 |
| WO2017194789A1 (en) * | 2016-05-13 | 2017-11-16 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| IL316169A (en) | 2016-10-27 | 2024-12-01 | Eisai R&D Man Co Ltd | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
-
2019
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt unknown
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 AU AU2019309938A patent/AU2019309938A1/en active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-01-14 IL IL310132A patent/IL310132B1/en unknown
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019309938A1 (en) | 2021-03-11 |
| IL310132A (en) | 2024-03-01 |
| KR20210039402A (ko) | 2021-04-09 |
| JP2024112859A (ja) | 2024-08-21 |
| IL280315B2 (en) | 2024-06-01 |
| IL310132B1 (en) | 2025-11-01 |
| CA3107370A1 (en) | 2020-01-30 |
| EP3826674A2 (en) | 2021-06-02 |
| US20210324056A1 (en) | 2021-10-21 |
| WO2020023530A2 (en) | 2020-01-30 |
| CN118924896A (zh) | 2024-11-12 |
| IL280315B1 (en) | 2024-02-01 |
| JP2021532126A (ja) | 2021-11-25 |
| WO2020023530A3 (en) | 2020-03-12 |
| JP7541505B2 (ja) | 2024-08-28 |
| CN112805031A (zh) | 2021-05-14 |
| MX2021000778A (es) | 2021-03-31 |
| BR112021001272A2 (pt) | 2021-04-27 |
| IL280315A (en) | 2021-03-25 |
| PH12021500006A1 (en) | 2021-09-13 |
| IL323583A (en) | 2025-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202019471A (zh) | 阿茲海默症之治療及預防方法 | |
| WO2016167263A1 (ja) | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| JP2018111723A (ja) | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 | |
| US20250163135A1 (en) | Biomarkers for alzheimer's disease treatment | |
| CN110214146B (zh) | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 | |
| TW202328178A (zh) | 抗Ａβ初原纖維抗體的皮下配製物及其使用方法 | |
| TW202430554A (zh) | 使用ｔａｕ ＰＥＴ水平之治療方法 | |
| JP2025506389A (ja) | ｐ－タウ１８１レベルを使用した治療方法 | |
| CN117940773A (zh) | 用于阿尔茨海默病治疗的生物标记物 | |
| RU2832167C2 (ru) | Способы лечения и предупреждения болезни альцгеймера | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| BR122025003268A2 (pt) | Métodos de tratamento e prevenção de doença de alzheimer | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 | |
| TW202518027A (zh) | 抗微生物肽 | |
| WO2022251048A1 (en) | Anti-amyloid beta antibodies and uses thereof | |
| TW202513583A (zh) | 使用抗Ａβ初原纖維抗體之治療方法 |